이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Decibel Therapeutics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Laurence Reid

최고 경영자

US$1.2m

총 보상

CEO 급여 비율	44.5%
CEO 임기	3.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.1yrs
이사회 평균 재임 기간	2.4yrs

최근 관리 업데이트

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

CEO 보상 분석

Laurence Reid 의 보수는 Decibel Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-US$63m
Mar 31 2023	n/a	n/a	-US$62m
Dec 31 2022	US$1m	US$548k	-US$63m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$801k	US$522k	-US$54m
Sep 30 2021	n/a	n/a	US$576k
Jun 30 2021	n/a	n/a	US$7m
Mar 31 2021	n/a	n/a	US$8m
Dec 31 2020	US$4m	US$574k	US$7m

보상 대 시장: Laurence 의 총 보상 ($USD 1.23M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Laurence 의 보상이 증가했습니다.

CEO

Laurence Reid (59 yo)

3.8yrs

테뉴어

US$1,232,276

보상

Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...

리더십 팀

이름	위치	테뉴어	보상	소유권
Laurence Reid	President & CEO	3.8yrs	US$1.23m	데이터 없음
Anna Trask	Executive VP & Chief People Officer	5.8yrs	US$618.23k	0% $ 0
John Lee	Executive VP & Chief Development Officer	7.1yrs	US$733.16k	0% $ 0
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
James Murphy	Interim CFO	less than a year	데이터 없음	데이터 없음
Elaine Cope	Vice President of Operations	2.1yrs	데이터 없음	데이터 없음
Geoff Horwitz	VP of Corporate Development & Head of Business Development	less than a year	데이터 없음	데이터 없음
Vassili Valayannopoulos	VP and Head of Clinical Research & Development	less than a year	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: DBTX 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Glenn Pierce	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음
Constance Cepko	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음
Guangping Gao	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음
Alan Cheng	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Ginty	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Greenberg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Dwight Bergles	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Matthew Kelley	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: DBTX 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Decibel Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Decibel Therapeutics, Inc. Announces Board Changes

High number of new directors

High number of new directors

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics, Inc. Announces Executive Changes

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령